Mishonga Itsva yeZvirwere Zvokuzvimba

Morningside Ventures nhasi yakazivisa kuvhurwa kweAdiso Therapeutics, kambani yekiriniki-nhanho yebiotechnology iri kusimudzira pombi yenovel therapeutics yakanangana nezvirwere zvinoputika. Morningside yakapa mari zvirongwa zvekusimudzira Adiso kusvika parizvino, nehurongwa hwekuenderera mberi nekutsigira kukurumidza kwekambani kukura kunofambira mberi.     

Adiso iri kusimudzira pombi yekugadzira mamorekuru ane nzira itsva dzekuita uye mhando imwe chete inorarama biotherapeutic products (SS-LBP), ichitsvaga lead indication in ulcerative colitis (UC), uye C. difficile infection (CDI). Pamusoro pezvirongwa zviviri zveChikamu 1 (UC & CDI) uye chirongwa cheChikamu chechipiri (UC), Adiso iri kugadzira chirongwa chitsva che inflammasome muchikamu chekutsvaga icho chiri kutanga kuongororwa mukuzvimba kwekufema, nenzvimbo dzakawanda dzeramangwana dzinogona kurapa dzekutsvaga.

Kambani iyi ine vashandi makumi maviri nevashanu avo, pasi peamburera yeMorningside, vakabudirira kuvhura zvitatu zveInvestigational New Drug (INDs) uye vakaisa mapepa akawanda pamwe nekuwana US FDA Fast Track Designation, zvakazotungamira mukuumbwa kweAdiso. Adiso achashanda pasi pehutungamiriri hweMukuru Mukuru achangogadzwa, Scott Megaffin. VaMegaffin vane makore anopfuura makumi matatu eruzivo rweindasitiri uye rekodhi yakabudirira mumabasa ehutungamiriri hwepamusoro paBristol-Myers Squibb, Pfizer, Schering-Plough, Adolor, Onconova, uye Churchill. Munguva pfupi yapfuura, VaMegaffin vakashanda seMukuru weAdastra Pharmaceuticals, kambani yeoncology yekiriniki-danho rekusimudzira, kwavakatungamira kambani kuita kutengeserana kwakabudirira neCothera Bioscience muna Gumiguru 25.  

"Zvakakosha zvisingaite zvinodiwa pakurapa zviripo pakurapa kutsva kunonangana neiyo biology yezvirwere zvinoputika pasina kukonzera systemic immunosuppression," akadaro Jason Dinges, Morningside Technology Advisory uye Adiso Board Member. “Adiso ari kubuda kunze kwegedhi aine zvirongwa zvekiriniki zvitatu zvinovimbisa kurapa ulcerative colitis nekudzivirira kubuda kweCDI. Tinotenda kuti pasi pehutungamiriri hwaScott uye nechikwata chine tarenda revagadziri vezvinodhaka, Adiso akagadzirira kubudirira. "

“KuAdiso tiri kurwisa zvirwere zvekuzvimba nenzira dzakasiyana uye neushingi. Isu tinoona chiitiko chitsva chevarwere, tichisimudzira kufambira mberi kunozivikanwa kwekurapa kwekuzvimba izvo zvinovimbisa kudzoreredza immune system yemunhu anenge auya, kuitira kuti chirwere chekuzvimba chisave chakanyanya kana kuti murwere asaite immunocompromised, "akadaro Scott Megaffin, CEO weAdiso Therapeutics. . "Ndine rukudzo kutungamira boka rakasiyana, repasi rose, uye rakazvipira kuAdiso mukuvandudza marapirwo akasarudzika akagadzirirwa kunyatso kumisa kusagadzikana kunokonzerwa nekuzvimba."

Mustafa A. Noor, MD, FACP abatanawo nechikwata chehutungamiriri cheAdiso. Dr. Noor anotora chinzvimbo cheMukuru Mukuru weChiremba, achiunza makore anopfuura 20 ehunyanzvi hwekuvandudza zvinodhaka munzvimbo dzakawanda dzekurapa munzvimbo dzakawanda dzekutanga kusvika pakati nepakati uye makambani epasi rose anosanganisira AMAG Pharmaceuticals, Akcea Therapeutics, Ipsen, Pfizer, Glaxo-Smith Kline. , uye Bristol Myers Squibb.

“Inflammatory dysregulation ndiyo musimboti wezvirwere zvakawanda zvakakomba uye kukuvadzwa kwazvinokonzeresa kunokanganisa hutano nekugara zvakanaka kwevarwere. Zvisarudzo zvemazuva ano zvekurapa hazvina kukwana kumisa kufambira mberi kwechirwere uye kuvandudza mararamiro ehupenyu nenzira yakachengeteka uye ine chinangwa, "akadaro Dr. Noor, CMO weAdiso Therapeutics. "Unhu hwakasiyana hweAdiso portfolio yekurapa hurwere hwekuzvimba hune mukana wekupedzisira wave wakakosha mishonga yevarwere. Kuvaka pamusoro pezvidzidzo zvekiriniki zvakabudirira uye zvekutanga zvekiriniki kusvika parizvino, ndinotarisira kutungamira matanho anotevera ekuvandudzwa kwekiriniki yepodfolio yedu nechikwata chine ruzivo revagadziri vekiriniki. "